The Albert Einstein Cancer Center has been and continues to be a major scientific resource for ECOG, providing pilot study data for the initiation of new ECOG clinical trials and providing laboratory resources for correlative studies. During the past grant period, ECOG studies in lymphoma, leukemia, breast, head and neck, melanoma and GI malignancies have been initiated based on pilot work from Einstein. Two of Einstein's investigators have obtained RO1 funding for laboratory research related to ECOG clinical trials, and Einstein has initiated 3 laboratory-based correlative studies in the leukemias, 1 in colon cancer and 1 in cervical cancer with partial funding provided by Einstein itself. Einstein has developed 3 core laboratories for ECOG: 1) immunophenotyping reference lab; 2) molecular biology of differentiation related to retinoic acid in leukemia; and 3) molecular biology of bcr-abl in ALL. Einstein, as a tertiary care facility, has maintained its accrual level, with 167 patients entered (140 from main institution) from 7/1/91 -6/30/92, and 391 patients continuing in follow-up. Forty to 52% of patients entered into clinical trials at Einstein are from minority races which in part reflects the efforts made by the institution to recruit such patients into clinical research trials utilizing minority race staff to encourage participation. More than 50% of study participants are women, and Einstein has developed ECOG studies specifically for malignancies of women. An Einstein investigator is the chair of the Gyn Onc Working Group. Einstein investigators have chaired 13 ECOG studies during the past grant period and 5 Einstein investigators have held disease or modality committee leadership roles (chair or co-chair) during the last grant period. The Einstein CGOP, which includes another major university center (SUNY-Stonybrook) and a large hospital in Long island (Nassau County Medial Center) and one in the Bronx (Our Lady of Mercy) has been productive participants in ECOG, in terms of accrual to studies and groupwide meeting attendance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA014958-20
Application #
2086301
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1999-04-30
Budget Start
1994-08-31
Budget End
1995-04-30
Support Year
20
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Bronx
State
NY
Country
United States
Zip Code
10461
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Smith, M R; Hong, F; Li, H et al. (2017) Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia 31:517-519
Schneider, Bryan P; Shen, Fei; Jiang, Guanglong et al. (2017) Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017:
Perez Horta, Zulmarie; Goldberg, Jacob L; Sondel, Paul M (2016) Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy 8:1097-117
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82

Showing the most recent 10 out of 146 publications